Circle Wants 40 Developing Markets. The Real Prize Isn't Remittances.

Forty countries. That's the number Jeremy Allaire attached to Circle's next expansion, and it's a bigger bet than the headline suggests.

The stablecoin issuer wants to plant USDC in roughly 40 developing markets, spread across Southeast Asia, Latin America, Africa, and the Middle East. Allaire, Circle's co-founder and CEO, frames it around demand. People in those regions want dollar-denominated money, and they want to move it across borders without handing a slice to correspondents and currency spreads.

He's not wrong about the demand. The World Bank puts the global average cost of sending $200 at about 6.2%, and Sub-Saharan Africa runs closer to 8%. Around 1.4 billion adults still sit outside the formal banking system. If you're holding a phone and a local currency that lost half its value in three years, a dollar token stops looking like crypto and starts looking like a savings account.

Forty Markets, One Currency Story

Circle isn't a scrappy startup anymore. It priced its IPO at $31 in June 2025 and traded above $100 within days, which tells you what public markets think of a dollar token with real reserves behind it. USDC circulates north of $60 billion. The company spent years building the boring machinery, things like reserve custody, monthly attestations, and state money transmitter licenses in nearly every US jurisdiction, while most token issuers skipped straight to the marketing.

And Washington handed it a tailwind. The GENIUS Act, signed in July 2025, set federal rules for payment stablecoins and gave bank-adjacent issuers a clearer path to scale. Europe's MiCA got there earlier. Regulation stopped being the enemy, which is a strange feeling for anyone who covered this sector in 2019.

Now here's where my beat kicks in. Healthcare is one of the last industries where cross-border payments are still genuinely broken, and almost nobody talks about it.

Think about a clinical trial running across sites in Kenya, Brazil, and the Philippines. Site payments go out by wire, take three to five days, get eaten by fees, and the documentation trail lives in somebody's inbox as a PDF. Think about a pharmaceutical shipment crossing four borders before it reaches a distributor in Lagos. Counterfeit medicine is a $4 billion-plus problem, and drug counterfeiting kills 500,000 people a year. That's the use case. Not the coffee shop. Not the speculative trade.

Where The Real Money Moves

Circle is walking into Tether's home turf with a better audit trail and a worse distribution network. That's the whole competitive picture in one sentence.

USDT already sits in the hands of millions of people in exactly the markets Allaire just named. Tether got there first, it got there cheap, and it got there without asking permission. Circle's advantage is that it can walk into a central bank or a health ministry and survive the due diligence. Those are different businesses wearing the same label.

So who wins if the 40-market push lands? Circle, obviously, because licensing at that scale is a moat that takes years to copy. Local fintechs and payment processors win too, since they get rails they could never build alone. The losers are the incumbents in the middle. Western Union, MoneyGram, and the correspondent banking layer have been charging 6% to 9% for a service that now takes seconds. That margin doesn't survive contact with a dollar token.

But there's a durable critique here that stablecoin people don't like hearing. The retail remittance story is the marketing. The revenue is in business-to-business flows: supplier payments, treasury moves, contractor payroll. Circle knows this. Consumer remittances are how you get a brand. Wholesale flows are how you get a balance sheet.

And then there's the question nobody in this industry wants to answer out loud. What happens to a central bank when a meaningful chunk of household savings decides it would rather sit in a token pegged to the dollar? Dollarization used to require policy decisions and decades. Now it requires a phone and a willingness to skip the local currency. I don't think Circle has a good answer for that, and I don't think it's Circle's job to have one.

Still, someone has to ask it before 40 markets become 40 test cases.

The Audit Trail Is The Product

Here's my takeaway, and it comes straight from the part of this beat that keeps me up at night.

The FDA doesn't care about your chain. It cares about your audit trail. The same is true of a health ministry, a hospital procurement officer, or a trial sponsor with a $200 million Phase III budget on the line. Nobody in healthcare buys a settlement layer because it's fast. They buy it because they can prove what happened, to whom, and when, and hand that proof to a regulator without flinching.

If Circle's expansion is really about moving $200 remittances faster, it's a fine business with a lot of competitors. If it's about becoming the settlement layer that pharmaceutical supply chains and clinical trial sponsors trust with their documentation, that's a different company at a different valuation.

Allaire has been careful to talk about access and dollar demand, which is the safe framing. The unspoken pitch is compliance infrastructure in places where compliance infrastructure barely exists. That's a much harder thing to build than a token. It's also the only version of this that lasts.

Forty markets in four regions, one dollar token, and a regulatory window that won't stay open forever. The race isn't about who mints fastest. It's about who can hand over the cleanest record when the inspector shows up.

Circle has been training for that race longer than most people realize.